To describe immunogenicity of the SCB-2019 vaccine in both participants with HIV infection and healthy participants; who received 2-dose vaccination series 3 or 6 weeks apart; in terms of SARS-CoV-2 neutralizing titers; 21 days after second vaccination with SCB-2019.

To describe immunogenicity of the SCB-2019 vaccine in both participants with HIV infection and healthy participants; who received 2-dose vaccination series 3 or 6 weeks apart; in terms of SARS-CoV-2 neutralizing titers; 21 days after second vaccination with SCB-2019.